Pseudomonas Aeruginosa

• USES: • For the temporary relief of symptoms including: • mucus congestion • stomach discomfort • fever • headache • cough • joint discomfort • occasional diarrhea • bladder discomfort These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.ICD-10: R05.9, R51.9

DIRECTIONS: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. Tamper Evident: Sealed for your protection. Do not use if seal is broken or missing.

Recent PubMed references pinned to Pseudomonas Aeruginosa as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Antimicrobial and antibiofilm effects of Lactobacillus cell-free supernatants against standard and antibiotic-resistant Pseudomonas aeruginosa and Staphylococcus aureus.
  Archives of microbiology · 2026 · Jasour SY, Mohammadhosseinzadeh F, Arefian E, et al.
  PMID 42250125DOI 10.1007/s00203-026-04836-3
• Mechanisms underlying pyogenic bacterial infections of the skin.
  Archives of microbiology · 2026 · Huang C, Yan X, Xu X, et al.
  PMID 42249917DOI 10.1007/s00203-026-04987-3
• Shaken batch cultures of Pseudomonas aeruginosa contain biofilm-like heterogeneity.
  Microbiology (Reading, England) · 2026 · Fritz BG, Christensen MH, Heiland L, et al.
  PMID 42240610DOI 10.1099/mic.0.001696
• WGS reveals high-risk clones of Pseudomonas aeruginosa harbouring extensive antimicrobial and predicted anti-phage defense systems recovered from diabetic foot ulcer patients in Egypt.
  BMC microbiology · 2026 · Amer MA, Darwish MM, Monir R, et al.
  PMID 42237234DOI 10.1186/s12866-026-05145-x
• Increased Carbapenem resistance and gene carriage in Pseudomonas aeruginosa clinical isolates after the COVID-19 pandemic in Egypt.
  Molecular biology reports · 2026 · Abdelrahim SS, Zaki S, Kotb DN, et al.
  PMID 42234289DOI 10.1007/s11033-026-12025-0
• Comparative genome analysis of carbapenemase-producing Pseudomonas aeruginosa: gene diversity, clonal distribution, and genome dynamics.
  Molecular genetics and genomics : MGG · 2026 · Noori Goodarzi N, Badmasti F
  PMID 42234203DOI 10.1007/s00438-026-02453-9
• Anti-biofilm and Efflux Pump Inhibitory Function of Fe(3)O(4)@SBA-3@Curcumin Nanoparticles on drug resistant isolates of Pseudomonas aeruginosa and Molecular Docking Analysis.
  Current microbiology · 2026 · Pabousi Sadatmahale A, Nouhi Kararoudi A, Zahmatkesh H, et al.
  PMID 42234182DOI 10.1007/s00284-026-04976-1
• Extensively and Pan-Drug Resistant Pseudomonas aeruginosa Strains from Burn Patients in Mexico City are Genetically Related to Isolates Recovered a Decade Earlier in Local Hospitals.
  Current microbiology · 2026 · Rojas-Rios R, Quiroz-Morales SE, Dominguez-Alvarez M, et al.
  PMID 42233983DOI 10.1007/s00284-026-04979-y

The 10 most recently updated of 230 ClinicalTrials.gov registrations naming Pseudomonas Aeruginosa as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa
  Available · Expanded access · Ottawa Hospital Research Institute
  NCT06798168updated 2026-06-04
• A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
  Recruiting · Phase 2 · Interventional · 435 enrolled · AstraZeneca
  NCT07088926updated 2026-06-03
• MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
  Not yet recruiting · Phase 1 · Interventional · 18 enrolled · MicrobiotiX Co., Ltd
  NCT07492771updated 2026-05-26
• Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
  Completed · Observational · 200 enrolled · Temple University
  NCT03510351updated 2026-05-22
• A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
  Completed · Phase 1 · Phase 2 · Interventional · 43 enrolled · Clarametyx Biosciences, Inc.
  NCT06159725updated 2026-05-05
• Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
  Recruiting · Observational · 600 enrolled · Centre Hospitalier Régional d'Orléans
  NCT06738771updated 2026-04-30
• Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
  Completed · Phase 4 · Interventional · 371 enrolled · Jin-Fu Xu
  NCT06093191updated 2026-04-17
• PMT for MDRO Decolonization
  Active not recruiting · Phase 2 · Interventional · 32 enrolled · University of Pennsylvania
  NCT05632315updated 2026-04-13
• Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis
  Recruiting · Phase 3 · Interventional · 30 enrolled · University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)
  NCT06870409updated 2026-03-19
• mexB Efflux Pump Gene Expression, Activity and Biofilm Formation in Clinical Isolates of Pseudomonas Aeruginosa
  Not yet recruiting · Observational · 80 enrolled · Assiut University
  NCT07469436updated 2026-03-17

Frequently asked questions

What is Pseudomonas Aeruginosa used for?

According to FDA labeling, Pseudomonas Aeruginosa carries indications including: USES: • For the temporary relief of symptoms including: • mucus congestion • stomach discomfort • fever • headache • cough • joint discomfort • occasional diarrhea • bladder discomfort These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.